Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma

Using a cancer registry to capture signals of adverse events following immune and targeted... International Journal of Clinical Pharmacy https://doi.org/10.1007/s11096-018-0665-1 RESEARCH AR TICLE Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma 1 2 2 2 3 João P. Aguiar  · Fábio Cardoso Borges  · Rodrigo Murteira  · Catarina Ramos  · Emanuel Gouveia  · 3 2 2,4 Maria José Passos  · Ana Miranda  · Filipa Alves da Costa Received: 9 January 2018 / Accepted: 17 May 2018 © Springer International Publishing AG, part of Springer Nature 2018 Background Toxicity of oncology treatments in real-life patients is frequently disregarded and hence underreported. Objective To characterize adverse events (AEs) of immunotherapy and targeted therapy reported in patients with locally advanced or metastatic melanoma. Setting District Hospital for Cancer treatment (Instituto Português de Oncologia de Lisboa Francisco Gentil). Method A retrospective cohort of melanoma patients was established, comprising adult patients diagnosed with malignant melanoma treated with immunotherapy or targeted therapy. Exposure was characterized by nature, time and inten- sity of exposure. To account for different exposure periods, person-time was used as unit of analysis. Main outcomes measure Occurrence of AEs. Results Data from 111 patients included in the cohort indicates the majority received immunotherapy regimens (CTLA-4, anti-PD-1 and combination therapy; (n = 70; 63.1%), among which anti-PD-1 were the predominant treatment. Pembrolizumab was the most frequently prescribed http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Clinical Pharmacy Springer Journals

Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma

Loading next page...
 
/lp/springer_journal/using-a-cancer-registry-to-capture-signals-of-adverse-events-following-h0StRNOv30
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Internal Medicine; Pharmacy
ISSN
2210-7703
eISSN
2210-7711
D.O.I.
10.1007/s11096-018-0665-1
Publisher site
See Article on Publisher Site

Abstract

International Journal of Clinical Pharmacy https://doi.org/10.1007/s11096-018-0665-1 RESEARCH AR TICLE Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma 1 2 2 2 3 João P. Aguiar  · Fábio Cardoso Borges  · Rodrigo Murteira  · Catarina Ramos  · Emanuel Gouveia  · 3 2 2,4 Maria José Passos  · Ana Miranda  · Filipa Alves da Costa Received: 9 January 2018 / Accepted: 17 May 2018 © Springer International Publishing AG, part of Springer Nature 2018 Background Toxicity of oncology treatments in real-life patients is frequently disregarded and hence underreported. Objective To characterize adverse events (AEs) of immunotherapy and targeted therapy reported in patients with locally advanced or metastatic melanoma. Setting District Hospital for Cancer treatment (Instituto Português de Oncologia de Lisboa Francisco Gentil). Method A retrospective cohort of melanoma patients was established, comprising adult patients diagnosed with malignant melanoma treated with immunotherapy or targeted therapy. Exposure was characterized by nature, time and inten- sity of exposure. To account for different exposure periods, person-time was used as unit of analysis. Main outcomes measure Occurrence of AEs. Results Data from 111 patients included in the cohort indicates the majority received immunotherapy regimens (CTLA-4, anti-PD-1 and combination therapy; (n = 70; 63.1%), among which anti-PD-1 were the predominant treatment. Pembrolizumab was the most frequently prescribed

Journal

International Journal of Clinical PharmacySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off